Clinical Trial Update: Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating an Epstein-Barr virus ferritin nanoparticle vaccine (gH/gL/gp42 with or without gp350) in healthy adults, and the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Infectious Mononucleosis

Drugs mentioned

• gH/gL/gp42-Ferritin Nanoparticle Vaccine
• gp350-Ferritin

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: EBV, Epstein-Barr Virus Infection | Phase 1 | Status: RECRUITING